Even given the fact that Australia is one of the highest vaccinated countries on the planet, a record number of deaths have been recorded in 2022. More people have died in Australia in the March 2022 quarter than any time in the last 41 years; total deaths nationwide are 18 percent higher in the quarter when compared to 2021, increasing from 36,100 to 46,200 deaths. Over this period around half the deaths were from Covid, even given the almost universal vaccination in the land of the long weekend.
https://www.stephenlbaxter.com/2013/02/25/australia-the-land-of-the-long-weekend-but-why/
“Despite the fact that the population of Australia is nearly universally vaccinated against SARS-CoV-2, TrialSite has reported that record numbers of deaths accumulated at the beginning of 2022. This is despite the universal protection of the vaccine. Yet breakthrough infections led to growing numbers of deaths in the most at-risk cohorts such as the elderly.
Now, mainstream media starts to acknowledge the trend. Recently, the Sydney Morning Herald reports in “COVID complications Push Australian deaths to highest number in 40 years,” that based on an analysis of the Australian Bureau of Statistics population data that total deaths nationwide are 18% higher in the quarter when compared to the prior year, rising from 36,100 to 46,200 deaths.
Labeled as “COVID-19’s hidden impact,” more people have died in Australia in the March quarter than any time in the last 41 years. Half the deaths in this period were from COVID despite an overwhelming vaccination rate. See the rates below:
|
Age Cohort |
% |
|
One Dose 16+ |
98.1% |
|
Two Dose 16+ |
96.4% |
|
Three Dose 16+ |
71.8% |
Australia is one of the most vaccinated populations in the world against COVID-19 yet as TrialSite reported earlier this year has experienced unprecedented pandemic related deaths. Does this trend evidence a failure of the COVID-19 vaccines?”
I believe that it does. Consider as well:
“Myocarditis occurs more commonly after receiving two doses of the COVID-19 mRNA vaccine, with Australian male teenagers and young adults being more susceptible. TrialSite has previously revealed that over 79,000 Australians have filed compensation claims for COVID-19 injuries. Despite an increase in mortality and hospitalization among the heavily immunized population, younger generations are still being encouraged to get vaccinated. Yet the logic, inputs and assumptions behind an explanatory risk-benefit analysis is not to be found.
As of September 20, 2022, 2.2 million children aged between five and 15 in Australia had received one dose of the vaccine, and almost 1.9 million had received two doses. TrialSite is investigating the most recent Australia COVID-19 vaccination safety report, which was published on September 23, 2022, to learn more about the adverse effects on children who are 17 years old or younger.
COVID-19 vaccine safety report
TrialSite's investigation of the Australia COVID-19 vaccine safety report found substantial numbers. There were roughly 4,280 reports from roughly 3.7 million doses of the mRNA vaccines Comirnaty (Pfizer) and Spikevax (Moderna) in children aged 12 to 17 up until September 18 of 2022. The most often reported responses included fever, nausea, dizziness, headaches, and chest pain.
There have been 1,630 reports from roughly 2.3 million doses of Comirnaty (Pfizer) and Spikevax (Moderna) given to children aged five to 11 years as of 18 September 2022. Chest pain, vomiting, fever, headaches, and abdominal pain were the most frequently experienced side effects.
There are three stages of myocarditis suspicion. Level 1 cases are those that have myocarditis confirmed by strong clinical evidence, such as the patient's symptoms and the outcomes of testing and imaging that support the diagnosis.
Based on a combination of symptoms and regular tests for heart problems, level 2 cases are most likely myocarditis. Based on symptoms and a doctor's evaluation that myocarditis is the most likely diagnosis in the absence of medical tests and investigations, level 3 cases are potentially myocarditis.
In the five-11 years old age group, there were 39 reports of myocarditis and/or pericarditis. After reviewing the reports, it was determined that four of them likely represented myocarditis, while the remaining seven likely represented pericarditis. TrialSite is investigating further the cases of myocarditis and myopericarditis brought on by the COVID-19 mRNA vaccinations given to children aged 12 to 17 in Victoria, Australia.
Out of a total of 1,424 cases, there have been 230 suspected myocarditis cases in teenagers aged 12 to 17 who received the Pfizer mRNA vaccine. The symptoms and results of standard tests for cardiac diseases indicate that myocarditis is most likely the cause of 64% (148) of the cases, which are level 2. Among 12 to 17-year-old adolescents, pericarditis may be present in 182 cases. 17% (33) of the 198 instances of adolescents between the ages of 12 and 17 who received the Spikevax vaccination from Moderna, also an mRNA vaccine, are thought to have myocarditis, and 70% (23) of those cases are in level 2. To date, a six-year-old patient is the youngest case to be labeled as likely myocarditis. 4% of 297 total cases of suspected pericarditis may have pericarditis.
After receiving two doses of the COVID-19 mRNA vaccine, there is an increase in the incidence of myocarditis, with male adolescents and young adults being more susceptible. After the second dose, there were about 24 cases per 100,000 doses of Spikevax and 13 cases per 100,000 doses of Comirnaty in male children aged 12 to 17. As for hospitalization, according to an Australian study published in August 2022, adolescent patients with vaccine-associated myocarditis spent an average of two days in the hospital.
TrialSite recently emphasized the importance of long-term risks associated with myocarditis. This condition must be monitored longitudinally to adequately understand true risk—and this is owed to the children and their family who were forced to get vaccinated in Australia.
Revise the Advice
When looking at the current state of affairs, age and gender differences in myocarditis may need to be taken into consideration when considering the COVID-19 primary (two-dose) vaccination roll-out to the adolescent population,
Most recently, children under five who do not have a higher risk of developing severe COVID-19 are not advised to receive vaccinations, according to the Australian Technical Advisory Group on Immunization (ATAGI). However, based on new information for this age group, this is still being considered.
The United Kingdom is one of the countries that follows the same recommendation. For children aged five to 11 who do not belong to a clinical risk group, the Joint Committee on Vaccination and Immunisation (JCVI) recommends a non-urgent offer of two 10 micrograms (mcg) doses of the Pfizer-BioNTech COVID-19 vaccine (Comirnaty).
According to a descriptive analysis of myocarditis submissions to the Vaccine Adverse Event Reporting System (VAERS), adolescents and young men were more at risk for myocarditis following the second dosage of the mRNA-based COVID-19 vaccine. This risk (again considering long-term consequences of myocarditis which are not included in nearly all analyses reviewed by this media) needs to be weighed against the advantages of receiving the COVID-19 vaccine. Hence, considering new information, ideally, policymakers will reassess current recommendations for COVID-19 vaccination in children under 17.”